Lancashire and South Cumbria
Formulary
Formulary
4 Central nervous system
04-09-01 Catachol-O-methyltransferase inhibitors
| Entacapone Comtess® |
|
Formulary
|
Tablets 200mg Adjunct to co-beneldopa or co-careldopa in Parkinson's disease. |
|
| Opicapone Ongentys® |
|
Formulary
|
Capsules 50mg Adjunctive therapy in adults with end-of-dose motor fluctuations who cannot be stabilised on preparations of levodopa/DOPA decarboxylase inhibitors. |
 LSCMMG: Opicapone NMR |
|
|
Links
BNF: Parkinson’s disease- How do you convert from co-beneldopa (Madopar®) prolonged-release capsules to dispersible tablets?
- LSCMMG: Apomorphine shared care guideline
- LSCMMG: Opicapone NMR
- LSCMMG: Restless Legs Syndrome in Adults in Primary Care
- LSCMMG: Restless Legs Syndrome in Adults in Primary Care
- LSCMMG: Restless Legs Syndrome in Adults in Primary Care
- MHRA Drug Safety Update April 2016: Apomorphine with domperidone: minimising risk of cardiac side effects
- MHRA: Apomorphine with domperidone: minimising risk of cardiac side effects
- MHRA: Dopamine agonists: pathological gambling, increased libido, and hypersexuality
- MHRA: Recent drug-name confusion
- MHRA: Recent drug-name confusion
- NICE CKS: Parkinson’s disease
- NICE NG71: Parkinson’s disease in adults
- NICE TA934: Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms
- NICE TA934:Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms
- Shared Care Guideline - Apomorphine